BDNF stimulates expression, activity and release of tissue-type plasminogen activator in mouse cortical neurons.
Brain-derived neurotrophic factor (BDNF) is a neurotrophic factor involved in neuronal development and synaptic plasticity. Although the physiological effects of BDNF have been examined in detail, target proteins which mediate its actions remain largely unknown. Here, we report that BDNF stimulates the expression of tissue-type plasminogen activator (tPA) in primary cultures of cortical neurons in a time- and concentration-dependent manner. Among the other members of the neurotrophin family, neurotrophin-4 (NT-4) and to a lesser extent neurotrophin-3 (NT-3) also increased tPA mRNA expression, while nerve growth factor (NGF) was devoid of any effect. Induction of tPA expression by BDNF is accompanied by an increase in the proteolytic activity of tPA associated with cortical neurons and a release of tPA into the extracellular space. Release of tPA induced by BDNF depends on extracellular Ca2+ since it is markedly reduced in the presence of ethylene glycol-bis(beta-aminoethylether)-N,N,N',N'-tetraacetic acid (EGTA). Up-regulation of tPA expression by BDNF is followed by the induction of plasminogen activator inhibitor 2 (PAI-2), an inhibitor of tPA. Together these results suggest that activation of tPA by BDNF may contribute to structural changes associated with neuronal development or synaptic plasticity.
Fiumelli
H
H
Laboratoire de Recherche Neurologique, Institut de Physiologie et Service de Neurologie du CHUV, Faculté de Médecine, Université de Lausanne, Switzerland.
Jabaudon
D
D
Magistretti
P J
PJ
Martin
J L
JL
D000818:Animals; D015152:Blotting, Northern; D019208:Brain-Derived Neurotrophic Factor / Q000494:pharmacology*; D002478:Cells, Cultured; D002540:Cerebral Cortex / Q000737:chemistry / Q000166:cytology / Q000502:physiology; D002614:Chelating Agents / Q000494:pharmacology; D003513:Cycloheximide / Q000494:pharmacology; D017931:DNA Primers; D003609:Dactinomycin / Q000494:pharmacology; D004533:Egtazic Acid / Q000494:pharmacology; D015870:Gene Expression / Q000502:physiology; D051379:Mice; D009414:Nerve Growth Factors / Q000494:pharmacology; D009473:Neuronal Plasticity / Q000502:physiology*; D009474:Neurons / Q000737:chemistry / Q000187:drug effects / Q000502:physiology*; D009479:Neuropeptides / Q000235:genetics; D020933:Neurotrophin 3; D017395:Plasminogen Activator Inhibitor 1 / Q000235:genetics*; D017396:Plasminogen Activator Inhibitor 2 / Q000235:genetics*; D011188:Potassium / Q000494:pharmacology; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D012333:RNA, Messenger / Q000032:analysis; D015842:Serine Proteinase Inhibitors / Q000235:genetics; D015843:Serpins / Q000235:genetics; D019789:Tetraethylammonium / Q000494:pharmacology; D000097522:Neuroserpin
D019208:Brain-Derived Neurotrophic Factor; D002614:Chelating Agents; D003513:Cycloheximide; D017931:DNA Primers; D003609:Dactinomycin; D004533:Egtazic Acid; D009414:Nerve Growth Factors; D009479:Neuropeptides; D020933:Neurotrophin 3; D017395:Plasminogen Activator Inhibitor 1; D017396:Plasminogen Activator Inhibitor 2; D011188:Potassium; D011500:Protein Synthesis Inhibitors; D012333:RNA, Messenger; D015842:Serine Proteinase Inhibitors; D015843:Serpins; D019789:Tetraethylammonium; D000097522:Neuroserpin; C073922:neurotrophin 4